肝癌放射免疫治疗疗效影响因素分析

FACTORS INFLUENCING THE EFFECT OF RADIOIMMUNOTHERAPY ON LIVER CANCER

本文采用多变量存活分析方法(Cox's回归模型)分析了33例手术不能切除的肝癌,经^(131)Ⅰ标记抗人肝癌铁蛋白抗体放射免疫治疗后影响生存时间的因素。初步结果表明肿瘤直径大小、^(131)Ⅰ单次放射剂量和肿瘤二期切除与生存时间密切相关。其1年和3年生存率肿瘤直径小于10cm者于大于10cm者相比,分别为84％对50％和63％对9％;^(131)Ⅰ单次放射剂量为5.55×10~8～9.25×10~8Bq与大于9.25×10~8Bq者相比,分别为86％对55％和50％对18％;肿瘤获二期切除者与未二期切除者相比,分别为80％对66％和80％对11％。

Thirty-three patients with surgically verified unreseotable hepatocellular carcinoma (HCO) receiving 131-I labeled anti-human HOC isoferritin antibody (131-1 FfcAb) treatment were studied. Multivariable analysis with Oox's regression model revealed that factors influencing survival after radioimmtmotherapy included tumor slzo, dosage of 131-I FtAb and second look resection. Survival in patients with tumor diameter ≤ 10 cm was higher than that with tumor diameter> 10cm(1-year survival: 84% versus 50%, 3-year survival: 63% versus 9%). Patients receiving 5.55× 108-9.25×10 Bq of 131-I FtAb each time yield better effect than that receiving>9.25×l08Bq(1-year survival: 68% versus 55%, 3-year survival: 50% versus 18%). After shrinkage of tumor, patients underwent second look resection had higher survival than that without second look resection (1-year survival: 80% versus 66%, 3-year survival: 80% versus 11%).